Collegium Pharmaceutical (US) noted an industry growth forecast of 8.0% in the US on August 9, 2025.
2 reports, 2 independent
Updated Aug 9
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Collegium Pharmaceutical (US) noted an industry growth forecast of 8.0% in the US on August 9, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Collegium Pharmaceutical received a specific industry growth forecast for the US market.1 source
Collegium Pharmaceutical underperformed market gains this year.1 source
Keep exploring
The entities involved
-
Collegium Pharmaceutical (United States)
company in Dedham, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- Simply Wall St.Collegium Pharmaceutical Second Quarter 2025 Earnings: Beats Expectations Explore Collegium Pharmaceutical's Fair Values from the Community and select yours Revenue: US$188.0m (up 29% from 2Q 2024).
- ZacksCollegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.68 per share, beating the Zacks Consensus Estimate of